NASDAQ:PCSA

Processa Pharmaceuticals (PCSA) Stock Forecast, Price & News

$0.56

+0.01 (+1.81%)

(As of 05/30/2023 ET)

Compare

Today's Range: $0.52
▼
$0.57
50-Day Range: $0.44
▼
$0.72
52-Week Range: $0.36
▼
$3.83

Volume: 35,908 shs
Average Volume: 201,922 shs
Market Capitalization: $13.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Processa Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 609.2% Upside
$4.00 Price Target
Short Interest: Healthy
0.79% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$20,000 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

608th out of 1,009 stocks

Pharmaceutical Preparations Industry

300th out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
Processa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Processa Pharmaceuticals has a forecasted upside of 609.2% from its current price of $0.56.
Amount of Analyst Coverage
Processa Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.79% of the outstanding shares of Processa Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Processa Pharmaceuticals has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Processa Pharmaceuticals has recently increased by 0.52%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Processa Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Processa Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PCSA.

2.7

News and Social Media Coverage

News Sentiment
Processa Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Processa Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
Only 2 people have added Processa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Processa Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
26.50% of the stock of Processa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.15% of the stock of Processa Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Processa Pharmaceuticals is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Processa Pharmaceuticals is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Processa Pharmaceuticals has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Processa Pharmaceuticals (NASDAQ:PCSA) Stock

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.

Receive PCSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PCSA Stock News Headlines

May 22, 2023 | finance.yahoo.com

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 18, 2023 | finance.yahoo.com

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 30, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

April 28, 2023 | baystreet.ca

Processa Positive on Trumpeting Convention Appearance

April 28, 2023 | finance.yahoo.com

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

April 14, 2023 | americanbankingnews.com

Insider Buying: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) CEO Buys 20,000 Shares of Stock

April 8, 2023 | americanbankingnews.com

Oppenheimer Comments on Processa Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:PCSA)

April 7, 2023 | americanbankingnews.com

Benchmark Cuts Processa Pharmaceuticals (NASDAQ:PCSA) Price Target to $4.00

May 30, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

April 5, 2023 | americanbankingnews.com

Processa Pharmaceuticals (NASDAQ:PCSA) PT Lowered to $3.00

April 4, 2023 | finance.yahoo.com

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Q4 2022 Earnings Call Transcript

April 3, 2023 | finanznachrichten.de

Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

March 30, 2023 | finance.yahoo.com

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

March 29, 2023 | americanbankingnews.com

Processa Pharmaceuticals (PCSA) Scheduled to Post Quarterly Earnings on Thursday

March 23, 2023 | finance.yahoo.com

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

March 17, 2023 | finance.yahoo.com

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

March 7, 2023 | finance.yahoo.com

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

February 21, 2023 | finance.yahoo.com

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

February 21, 2023 | finance.yahoo.com

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

February 15, 2023 | finance.yahoo.com

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

February 10, 2023 | finance.yahoo.com

Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

February 3, 2023 | benzinga.com

Thinking about buying stock in Nordstrom, TMC the metals company, Gracell Biotechnologies, Processa Pharmaceuticals, or Mullen Automotive?

January 4, 2023 | finance.yahoo.com

Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.

December 29, 2022 | insidermonkey.com

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Q3 2022 Earnings Call Transcript

December 15, 2022 | marketwatch.com

Processa Pharmaceuticals Stock Climbs on Latest Data from Gastroparesis Study

December 14, 2022 | finance.yahoo.com

Processa Pharma's Investigational Candidate Improves Gastroparesis-Associated Clinical Symptoms

December 14, 2022 | msn.com

Processa jumps 11% after mid-stage data for gastroparesis candidate

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PCSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PCSA Company Calendar

Last Earnings: 3/30/2023
Today: 5/30/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PCSA
CUSIP: N/A
CIK: 1533743
Web: www.processapharmaceuticals.com
Phone: (443) 776-3133
Fax: 443-288-4420
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +644.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -152.54%
Return on Assets: -136.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.65
Quick Ratio: 5.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.47 per share
Price / Book: 1.14

Miscellaneous

Outstanding Shares: 24,530,000
Free Float: 18,030,000
Market Cap: $13.18 million
Optionable: Not Optionable
Beta: 0.16

Key Executives

David Young
President & Chief Executive Officer

R. Michael Floyd
Chief Operating Officer

Jim Stanker
Chief Financial & Accounting Officer

Kayla Parks
Associate-Clinical Research

Smythe-Pinkerton Shanique
Director-Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PCSA Stock - Frequently Asked Questions

Should I buy or sell Processa Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCSA shares.
View PCSA analyst ratings or view top-rated stocks.
What is Processa Pharmaceuticals' stock price forecast for 2023?: 3 equities research analysts have issued 12-month price targets for Processa Pharmaceuticals' stock. Their PCSA share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 644.2% from the stock's current price.
View analysts price targets for PCSA or view top-rated stocks among Wall Street analysts.
How have PCSA shares performed in 2023?: Processa Pharmaceuticals' stock was trading at $1.10 at the start of the year. Since then, PCSA stock has decreased by 51.1% and is now trading at $0.5375.
View the best growth stocks for 2023 here.
When is Processa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our PCSA earnings forecast.
How were Processa Pharmaceuticals' earnings last quarter?: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) posted its earnings results on Thursday, March, 30th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.10.

What is Processa Pharmaceuticals' stock symbol?: Processa Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCSA."
Who are Processa Pharmaceuticals' major shareholders?: Processa Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Two Sigma Securities LLC (0.26%). Insiders that own company stock include David Young, James E Besser, James H Stanker, Justin W Yorke, Patrick Lin and Robert Michael Floyd.
View institutional ownership trends.
How do I buy shares of Processa Pharmaceuticals?: Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Processa Pharmaceuticals' stock price today?: One share of PCSA stock can currently be purchased for approximately $0.54.
How much money does Processa Pharmaceuticals make?: Processa Pharmaceuticals (NASDAQ:PCSA) has a market capitalization of $13.18 million. The company earns $-27,420,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis.
How can I contact Processa Pharmaceuticals?: Processa Pharmaceuticals' mailing address is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. The official website for the company is www.processapharmaceuticals.com. The company can be reached via phone at (443) 776-3133, via email at plin@processapharma.com, or via fax at 443-288-4420.

This page (NASDAQ:PCSA) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial